Pharmacy Times

JUNE 27, 2025

On January 16, 2025, the FDA approved acalabrutinib (Calquence; AstraZeneca) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). January 16, 2025. Accessed May 14, 2025.

FDA

Pharmacy Times

JUNE 9, 2025

These conclusions were presented as part of an abstract from the open-label, phase 3 CheckMate 816 trial (NCT02998528) at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, and subsequently published in the Journal of Clinical Oncology. Last Updated January 24, 2025. Accessed June 9, 2025.

Chemotherapy

Pharmacy Times

JUNE 16, 2025

1 The findings were presented at the Revolutionizing Atopic Dermatitis (RAD) 2025 conference held in Nashville, Tennessee. RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years.

Compounding Pharmacies

Pharmacy Times

JUNE 30, 2025

REMS ensured drug safety by requiring certified hospitals to have tocilizumab for severe adverse events management. Accurate product labeling and ongoing safety monitoring remain essential for patient safety in CAR T therapies. Released June 27, 2025. Accessed June 30, 2025. Last Updated May 20, 2025. News Release.

FDA

Pharmacy Times

JULY 22, 2025

In a sign of alixorexton’s tolerability, over 95% of patients who participated in this portion of the trial elected to join the ongoing 7-week, open-label extension. Released July 21, 2025. Accessed July 22, 2025. Last Updated May 20, 2025. Accessed July 22, 2025. Accessed July 22, 2025. News Release.

Compounding Pharmacies

Pharmacy Times

JUNE 23, 2025

Soefje, PharmD, MBA, BCOP, during the Hematology/Oncology Pharmacy Association (HOPA) 2025 Annual Conference in Portland, Oregon. Additionally, ANDA submissions should extrapolate the RLD safety and effectiveness data for drugs with the same active ingredients, dosage forms, strengths, routes, and labeling. REFERENCE Soefje SA.

FDA

European Pharmaceutical Review

JUNE 26, 2025

Nine patients with advanced adenocarcinomas received a single treatment cycle of the drug candidate 177 Lu-labeled FAPI-RGD. The findings were presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting and published in the Journal of Nuclear Medicine. percent of patients. Xiang et al.

Labelling

The Nontraditional Pharmacist

JULY 1, 2025

It’s 2025. And those are sites, sometimes those are hospitals, sometimes they’re physician’s offices, there’s for-profit, clinical research sites out there. And ultimately, it’s to ensure we get the data because the data are ultimately what turns into your FDA approved label and demonstrates what you need.

FDA

Pharmacy Times

JULY 10, 2025

Relapse risk factors include prior hospitalizations, long illness duration, and antipsychotic polypharmacy, emphasizing the need for effective maintenance treatments. Maintaining stability in schizophrenia is a major clinical challenge—each relapse can disrupt functioning, burden caregivers, and elevate hospitalization risk.

FDA

Drug Topics

JULY 7, 2025

Treasure Island (FL): StatPearls Publishing; 2025 Jan-. AI-Driven CGM Insights Improved Glycemic Control | ADA 2025 Brian Nowosielski July 1st 2025 Article In an abstract presented at the American Diabetes Association 85th Scientific Sessions, researchers tested the effectiveness of an AI-driven program for improving glycemic control.

Compounding

Pharmacy Times

JUNE 20, 2025

There are too many drug approvals, label updates, and new data published for even the most skilled and experienced oncology pharmacist to keep up with, let alone those still building their baseline knowledge. Accessed May 15, 2025. Accessed May 15, 2025. Accessed May 15, 2025. Accessed May 15, 2025. August 8, 2024.

Compounding

PharmTech

JUNE 23, 2025

Thakar Varanya Chaiyaperm View All News Article Bulk drug calculations for different types of active moieties and drugs require different calculations and labeling. Part two discussion describes a simple medication order and demonstrates calculations and labeling for each bulk drug type. Pluta Nishant B. Mole calculations.

Compounding

Hospital Pharmacy Europe

APRIL 14, 2025

Key findings in this review emphasised that most of these children and young people died before reaching the hospital, with 46% receiving inadequate asthma care. Some deaths occurred due to cardiac arrest, predominantly outside of hospitals, with 29 children (58%) having unsuccessful cardiopulmonary resuscitation. Accessed March 2025].

Health and Personal Care Stores

Pharmacy Times

JULY 17, 2025

1 Image Credit: Syahrir | stock.adobe.com Gabapentin is FDA approved for partial seizures and postherpetic neuralgia, but has widespread off-label use for various chronic pain conditions, including back pain. Published July 2, 2025. doi: 10.1136/rapm-2025-106577 [link] George J. Published July 10, 2025. MedPage Today.

Compounding Pharmacies

Pharmacy Times

JULY 1, 2025

Tafamidis, a selective transthyretin stabilizer, significantly reduces mortality and hospitalizations in ATTR-CM patients. Tafamidis] was compared to placebo and reduced all-cause mortality by 30% and [cardiovascular] hospitalizations by 32% over 30 months.

HIV Treatment and Prevention Agents

Pharmacy Times

JULY 15, 2025

Updated May 23, 2025. Accessed July 15, 2025. July 10, 2025. Accessed July 15, 2025. July 10, 2025. months progression-free survival in real-world RRMM patients, consistent with KarMMa trial results. Efficacy and safety study of bb2121 in subjects with relapsed and refractory multiple myeloma (KarMMa).

Immunization

Pharmacy Times

JULY 7, 2025

1 DOORwaY 90 Study Results The approval was supported by data from the prospective, multicenter, open-label, single-arm DOORwaY 90 study that evaluated the safety and efficacy of Y-90 resin microspheres in individuals with unresectable HCC. July 7, 2025. Accessed July 7, 2025. Accessed July 7, 2025. Accessed July 7, 2025.

FDA

Pharmacy Times

JULY 22, 2025

Personalized drug selection can lead to faster symptom control, fewer hospitalizations, and improved adherence—all of which contribute to better outcomes and a more streamlined care process. Accessed July 21, 2025. Accessed July 21, 2025. Accessed July 21, 2025. European Medicines Agency. link] NHS England.

Compounding Pharmacies

Pharmacy Times

JUNE 16, 2025

3,4 How this pricing model will be implemented and whether pharmaceutical manufacturers will be able to meet the expectations of the 2025 executive order, if upheld, is uncertain. May 12, 2025. Accessed May 13, 2025. May 12, 2025. Accessed May 13, 2025. May 7, 2025. Accessed May 13, 2025. May 2, 2025.

Compounding Pharmacies

Pharmacy Times

JUNE 23, 2025

1 Image credit: Cynthia | stock.adobe.com The discussion featured Vivian Fonseca, MD, of the Tulane University School of Medicine, who presented an overview of tirzepatide based on the FDA-approved label and clinical guidelines. Presented: 85th Scientific Sessions of the American Diabetes Association; June 23, 2025; Chicago, Illinois.

HIV Treatment and Prevention Agents

Pharmaceutical Technology

JULY 29, 2025

July 29, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The therapy is administered subcutaneously once a week, ensuring a sustained release of active, unmodified somatropin. This important milestone is the first of many planned label expansions supporting our goal to become the leading endocrinology rare disease company.”

FDA

Pharmacy Times

JUNE 23, 2025

Completion Date (Estimated): May 2025 Lorundrostat is an oral, highly selective aldosterone synthase inhibitor (ASI) under development for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), as well as CKD and obstructive sleep apnea. Updated February 21, 2025. Accessed June 17, 2025.

Compounding Pharmacies

Pharmacy Times

JULY 2, 2025

The CRL was received after OLC’s initial Prescription Drug User Fee Act date of June 28, 2025, and cited for deficiencies that are unrelated to OLC itself. 2,4 The open-label, single-arm, multicenter, multidose study enrolled 86 patients with CKD and hyperphosphatemia receiving maintenance hemodialysis. June 30, 2025.

FDA

Pharmacy Times

JULY 15, 2025

Just to share a little bit more about our medication packets: these packets are labeled by date and time, and they come in a monthly pill dispenser box. Those packets come right out of the box, and you're able to tear them away.

Compounding Pharmacies

Pharmacy Times

JULY 10, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Specialty Pharmacies

Pharmaceutical Technology

JUNE 27, 2025

June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Label updates have been approved for BMS’ CAR T cell therapies, Breyanzi and Abecma, to treat multiple myeloma. The regulatory agency has also given approval to the removal of the REMS requirement from the product labels.

Labelling

Pharmacy Times

JUNE 30, 2025

The findings from a phase 2 study (NCT04988815) were presented at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago. 2-5 In the multicenter, phase 2, open-label prospective study, researchers investigated ropeg-IFN-α2b treatment in patients with profibrotic MF or DIPSS low-intermediate-1 risk MF. June 3, 2025.

Compounding Pharmacies

Pharmaceutical Commerce

JUNE 17, 2025

Intelligent medication management systems using RWD help hospitals forecast demand, respond to crises, and minimize medication expiration and loss, ultimately improving patient care and operational efficiency. million drugs are given or prescribed annually in hospital emergency departments alone.

Health and Personal Care Stores

Pharmacy Times

JULY 7, 2025

Limitations included open-label design and dosage constraints, but the multicountry approach enhanced generalizability and external validity. 1 “The limitations of this study were it being open-label, allowing potential assessment biases and the absence of blinded assessment of clinical endpoints. Accessed July 1, 2025.

Compounding Pharmacies

Pharmacy Times

JUNE 5, 2025

Detect-A-Dose lid-label cover enhances medication recognition, reducing packaging errors through a contrasting visual pattern. Concerningly, preventable adverse events due to medication errors cause an estimated 44,000 to 98,000 hospital deaths annually, more than the number attributed to motor vehicle accidents.

Packaging

Pharmacy Times

JULY 18, 2025

1 STARGLO is an open-label, multicenter, randomized phase 3 STARGLO clinical trial which compared the efficacy and safety of glofitamab and GemOx (Glofit-GemOx) with rituximab (Rituxan; Genentech) and GemOx (R-GemOx) in patients with R/R DLBCL who have received at least 2 prior lines of treatment. July 18, 2025. Accessed July 18, 2025.

FDA

Pharmacy Times

JUNE 11, 2025

Completion Date (Estimated): December 31, 2025 TRUST-II Trial Name: Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II) ClinicalTrials.gov ID: NCT04919811 Sponsor: Nuvation Bio Inc. June 11, 2025. Accessed June 11, 2025. June 11, 2025. Accessed June 11, 2025. Accessed June 11, 2025.

FDA

Pharmacy Times

JULY 3, 2025

Typically, it's a white-labeled experience, so it has the look and feel of that digital therapeutic throughout the entire experience. What we do is create a very nice UI/UX digital experience so we can onboard patients, receive payment, and then hand them off to the digital therapeutic.

Compounding Pharmacies

Pharmacy Times

JUNE 9, 2025

At the 2025 American Society of Health-System Pharmacists (ASHP) Pharmacy Futures meeting, 4 pharmacy leaders from major health systems gathered for a candid panel discussion about the rapidly evolving role of pharmacists in managing advanced therapeutics, including cell and gene therapies. Accessed June 9, 2025.

Compounding Pharmacies

Pharmacy Times

JUNE 12, 2025

Accessed June 12, 2025. Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: A single-arm, open-label, phase 3 trial (ENVISION). February 1, 2025. June 12, 2025. Accessed June 12, 2025. June 12, 2025. Accessed June 12, 2025. Front Oncol.

FDA

Pharmacy Times

JULY 9, 2025

The FDA has approved an updated label with a new recommended titration dosing schedule for donanemab-azbt (Kisunla; Eli Lilly and Company) for once-monthly amyloid-targeting therapy for adults that experience early symptomatic Alzheimer disease (AD). July 9, 2025. Accessed July 9, 2025. Accessed July 9, 2025. Mayo Clinic.

Labelling

Pharmacy Times

JUNE 9, 2025

These findings, which were presented at the 2025 American Society of Clinical Oncology in Chicago, Illinois, suggest that omitting carboplatin from treatment regimens could be an efficacious de-escalated neoadjuvant strategy in this patient population. 43, 2025 (suppl 17; abstr LBA500). Accessed June 6, 2025. J Clin Oncol.

Compounding Pharmacies